| Bioactivity | Pinatuzumab vedotin, an antibody-drug conjugate (ADC), is a CD22 humanized monoclonal antibody Pinatuzumab (HY-P99230) conjugated to VcMMAE (HY-15575). Pinatuzumab vedotin has antitumor activities[1]. |
| CAS | 1313706-14-7 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Ranjana H Advani, et al. Phase I Study of the Anti-CD22 Antibody–Drug Conjugate Pinatuzumab Vedotin with/without Rituximab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma. Clinical Trial Clin Cancer Res. 2017 Mar 1;23(5):1167-1176. |